华蟾素联合XELOX方案治疗晚期结肠癌的临床疗效观察
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:


Clinical effect of cinobufotalin capsule combined with XELOX chemotherapy on treatment of advanced colorectal cancer
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    【摘要】〓目的〓 观察华蟾素胶囊联合XELOX方案治疗晚期结肠癌的临床疗效。方法〓将96例晚期结肠癌患者分为观察组和对照组各48例,观察组采用XELOX方案化疗时,同时口服华蟾素胶囊,对照组则单用XELOX方案化疗,比较两组的近期有效率、生活质量变化及不良反应情况。结果〓观察组疾病控制率(917%)与对照组(688%)比较,差异有统计学意义(P<0001);观察组生活质量改善率(875%)高于对照组(688%),差异亦有统计学意义(P<001);观察组不良反应较对照组明显减轻,差异有统计学意义(P<005)。结论〓华蟾素胶囊联合XELOX化疗能明显提高晚期结肠癌的疾病控制率,改善患者的生活质量,并减轻化疗不良反应,可在临床推广应用。

    Abstract:

    【Abstract】〓Objective〓To observe the clinical effect of cinobufotalin capsule combined with XELOX chemotherapy in treatment of advanced colorectal cancer. Methods〓 96 advanced colon cancer patients were divided into observation group and control group. The observation group (48 cases) was treated with XELOX chemotherapy, and oral cinobufotalin capsule. The control group was treated with XELOX chemotherapy. The shortterm effective rate, quality of life and adverse reaction were observed. Results〓 The disease control rate of observation group (917%) was higher than that of control group (688%) (P<0001). The improvement rate of quality of life of observation group and control group were 875% and 688% (P<001). The adverse reaction in observation group was significantly reduced compared with that of the control group (P<005). Conclusion〓 The cinobufotalin capsule combined with XELOX chemotherapy for advanced colon cancer can significantly improve the disease control rate and quality of life of patients, and reduce the adverse reaction of chemotherapy.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2017-11-10
您是第位访问者
版权所有:《西部医学》编辑部     蜀ICP备18038379号-4
地址:四川省成都市武侯区小天竺街75号财富国际18F-1号    邮政编码:610041
电话:028-85570072/85588403    E-mail:xbyxqk@163.com
技术支持:北京勤云科技发展有限公司